Related Experiment Video
Updated: Jul 3, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Ursodeoxycholic acid for preventing parenteral nutrition-associated cholestasis in neonates: A systematic review and
Rajendra Prasad Anne1, Srikanth Puttaiah Kadyada2, Abhishek Somasekhara Aradhya3
1Neonatology, Kasturba Medical College, Manipal Academy of Higher Education (MAHE), Manipal, India.
Insights
Ursodeoxycholic acid (UDCA) did not prevent cholestasis in neonates receiving parenteral nutrition. While UDCA improved feed tolerance and reduced bilirubin levels, the evidence quality was very low, precluding definitive conclusions.
Area of Science:
- Neonatal Medicine
- Gastroenterology
- Pharmacology
Background:
- Parenteral nutrition-associated cholestasis (PNAC) is a concern in neonates.
- Ursodeoxycholic acid (UDCA) is used for treating PNAC, but its preventive role is not established.
Conclusions:
- Definitive conclusions on UDCA for PNAC prevention in neonates cannot be made due to very low-quality evidence.
- Further high-quality research is needed to clarify the role of UDCA in preventing PNAC.
Background:
While ursodeoxycholic acid is used in treating parenteral nutrition-associated cholestasis (PNAC) in neonates, its role in prevention is unclear.
Objectives:
In this systematic review and meta-analysis, we attempted to determine the role of ursodeoxycholic acid in preventing PNAC in neonates.
Methods:
PubMed, Embase, Cochrane Library, Scopus, and CINAHL databases were searched on September 16, 2023, for interventional studies comparing ursodeoxycholic acid with placebo.
Results:
Of the 6180 unique records identified, five studies were eligible for inclusion (three randomised and two nonrandomised). Evidence from randomised trials showed that ursodeoxycholic acid prophylaxis did not reduce cholestasis, mortality, sepsis, and necrotising enterocolitis. Ursodeoxycholic acid prophylaxis reduced feed intolerance (RR 0.23 (0.09, 0.64); 1 RCT, 102 neonates), peak conjugated bilirubin levels (MD -0.13 (-0.22, -0.04) mg/dL; 1 RCT, 102 neonates), and time to full enteral feeds (MD -2.7 (-5.09, -0.31) days; 2 RCTs, 76 neonates). There was no decrease in hospital stay and parenteral nutrition duration. Data from nonrandomised studies did not show benefit in any of the outcomes. The certainty of the evidence was low to very low.
Conclusion:
Because of the very low-quality evidence and lack of evidence on critical outcomes, definitive conclusions could not be made on using ursodeoxycholic acid to prevent parenteral nutrition-associated cholestasis in neonates.
Related Concept Videos
Parentral Nutrition: Centeral and Peripheral Parental Nutrition
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
Enteral Nutrition I: Orogastric and Nasogastric Feeding
Orogastric (OG) and nasogastric (NG) feeding are two standard methods used for enteral nutrition. Enteral nutrition is often preferred over...
Prevention of Further Absorption of Poison
Routes of Drug Administration: Parenteral
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...

